Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 10, 2012, Pages 711-718

  Hu, Wang Xiong ^a   Chen, He Ping ^b   Yu, Kang ^a   Shen, Lu Xi ^c   Wang, Chao Yan ^a   Su, Shi Zhen ^a   Sui, Wen Jun ^a   Shan, Da Ming ^a   Li, Hong Zhi ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

erbB2; gene therapy; immunotherapy; recombinant gene; scFv; T cell; tumor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY IMMUNOGLOBULIN FC FRAGMENT CD28 CD3 ZETA FUSION PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTOTOXICITY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ARTIFICIAL GENE FUSION; BREAST NEOPLASMS; CELL LINE, TUMOR; GENETIC THERAPY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; LYMPHOMA, T-CELL; MCF-7 CELLS; MICE; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFECTION;

EID: 84870856909     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1246     Document Type: Article

References (58)

1. Huang TH, Morrison SL. A trimeric anti-HER2/neu ScFvand tumor necrosis factor-alpha fusion protein inducesHER2/neu signaling and facilitates repair of injured epithelia.J Pharmacol Exp Therapeut 2006;316:983.
2. Yu D, Hung MC. Overexpression of ErbB2 in cancer andErbB2-targeting strategies. Oncogene 2000;19:6115.
3. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene inhuman breast cancer and its clinical significance. Eur JCancer 1998;34:791.
4. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpressionof c-erbB2 is an independent marker of resistance to endocrinetherapy in advanced breast cancer. Br J Cancer 1999;79:1220.
5. Kershaw MH, Westwood JA, Parker LL, et al. A phase Istudy on adoptive immunotherapy using gene-modifiedT cells for ovarian cancer. Clin Cancer Res 2006;12:6106.
6. Gravalos C, Jimeno A. HER2 in gastric cancer: A newprognostic factor and a novel therapeutic target. Ann Oncol2008;19:1523.
7. Ming-Kai X, Cheng-Gang Z. Gene expression and functionstudy of fusion immunotoxin anti-Her-2-scFv-SEC2 inEscherichia coli. Appl Microbiol Biotechnol 2006;70:78.
8. Cai Z, Zhang H, Liu J, et al. Targeting erbB receptors. SeminCell Dev Biol 2010;21:961.
9. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab inthe treatment of HER2-amplified breast cancer. InvestigNew Drugs 2005;23:391.
10. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvanttherapy with trastuzumab for HER-2/neu-positive breastcancer. Oncologist 2006;11:857.
11. Osako T, Ito Y, Takahashi S, et al. Efficacy and safety oftrastuzumab plus capecitabine in heavily pretreated patientswith HER2-positive metastatic breast cancer. Cancer ChemotherPharmacol 2008;62:159.
12. Wright MJ, Deonarain MP. Phage display of chelating recombinantantibody libraries. Mol Immunol 2007;44:2860.
13. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapyfor cancer: The next generation of gene-engineered immunecells. Tissue Antigens 2009;74:277.
14. Beckman RA, Weiner LM, Davis HM. Antibody constructsin cancer therapy: Protein engineering strategies to improveexposure in solid tumors. Cancer 2007;109:170.
15. Schule J, Bergkvist L, Hakansson L, et al. Down-regulationof the CD3-zeta chain in sentinel node biopsies from breastcancer patients. Breast Cancer Res Treat 2002;74:33.
16. Shibuya TY, Nugyen N, McLaren CE, et al. Clinical significanceof poor CD3 response in head and neck cancer. ClinCancer Res 2002;8:745.
17. Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapyfor follicular lymphoma using genetically modifiedCD20-specific CD8 + cytotoxic T lymphocytes. Mol Ther2004;9:577.
18. Schirrmann T, Pecher G. Specific targeting of CD33 (+) leukemiacells by a natural killer cell line modified with a chimericreceptor. Leuk Res 2005;29:301.
19. Hombach A, Wieczarkowiecz A, Marquardt T, et al. TumorspecificT cell activation by recombinant immunoreceptors:CD3 zeta signaling and CD28 costimulation are simultaneouslyrequired for efficient IL-2 secretion and can be integratedinto one combined CD28/CD3 zeta signalingreceptor molecule. J Immunol 2001;167:6123.
20. Hu S, Li L, Qiao J, et al. Codon optimization, expression,and characterization of an internalizing anti-ErbB2 singlechainantibody in Pichia pastoris. Protein Expr Purif 2006;47:249.
21. Warrens AN, Jones MD, Lechler RI. Splicing by overlapextension by PCR using asymmetric amplification: An improvedtechnique for the generation of hybrid proteins ofimmunological interest. Gene 1997;186:2.
22. Jones ML, Barnard RT. Chimerization of multiple antibodyclasses using splice overlap extension PCR. Biotechniques2005;38:181.
23. Heckman KL, Pease LR. Gene splicing and mutagenesis byPCR-driven overlap extension. Nat Protoc 2007;2:924.
24. Cox MA, Zajac AJ. Shaping successful and unsuccessful CD8T cell responses following infection. J Biomed Biotechnol2010;2010:159152.
25. Faurie C, Rebersek M, Golzio M, et al. Electro-mediated genetransfer and expression are controlled by the life-time ofDNA/membrane complex formation. J Gene Med 2010;12:117.
26. Maurisse R, De Semir D, Emamekhoo H, et al. Comparativetransfection of DNA into primary and transformed mammaliancells from different lineages. BMC Biotechnol 2010;10:9.
27. Cooper LJ, Ausubel L, Gutierrez M, et al. Manufacturing ofgene-modified cytotoxic T lymphocytes for autologous cellulartherapy for lymphoma. Cytotherapy 2006;8:105.
28. Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonalT cell immunotherapy of lymphomas, using a chimericT cell receptor possessing CD28 and CD137costimulatory domains. Human Gene Ther 2007;18:712.
29. Escoffre JM, Portet T, Wasungu L, et al. What is (still not)known of the mechanism by which electroporation mediatesgene transfer and expression in cells and tissues. Mol Biotechnol2009;41:286.
30. Escoffre JM, Bellard E, Golzio M, et al. Transgene expressionof transfected supercoiled plasmid DNA concatemers inmammalian cells. J Gene Med 2009;11:1071.
31. Maucksch C, Bohla A, Hoffmann F, et al. Transgene expressionof transfected supercoiled plasmid DNA concatemersin mammalian cells. J Gene Med 2009;11:444.
32. Jain NK, Roy I. Effect of trehalose on protein structure.Protein Sci 2009;18:24.
33. Matsuki N, Takeda M, Ishikawa T, et al. Activation of caspasesand apoptosis in response to low-voltage electricpulses. Oncol Rep 2010;23:1425.
34. Meehan KR, Wu J, Webber SM, et al. Development of aclinical model for ex vivo expansion of multiple populationsof effector cells for adoptive cellular therapy. Cytotherapy2008;10:30.
35. Jensen MC, Clarke P, Tan G, et al. Human T lymphocytegenetic modification with naked DNA. Mol Ther 2000;1:49.
36. Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancergene therapy approach utilizing an anti-erbB-2 single-chainantibody-encoding adenovirus (AD21): A phase I trial. ClinCancer Res 2000;6:3081.
37. Clemenceau B, Congy-Jolivet N, Gallot G, et al. Antibodydependentcellular cytotoxicity (ADCC) is mediated bygenetically modified antigen-specific human T lymphocytes.Blood 2006;107:4669.
38. Arafat WO, Gomez-Navarro J, Buchsbaum DJ, et al. Effectivesingle chain antibody (scFv) concentrations in vivo viaadenoviral vector mediated expression of secretory scFv.Gene Ther 2002;9:256.
39. Barker SD, Dmitriev IP, Nettelbeck DM, et al. Combinedtranscriptional and transductional targeting improves thespecificity and efficacy of adenoviral gene delivery to ovariancarcinoma. Gene Ther 2003;10:1198.
40. Guo MG, Jiang MH, Yang Q, et al. Gene therapy for ovariancancers by adenovirus-mediated complete antibody gene.Zhonghua Yi Xue Za Zhi 2004;84:1147.
41. Shen YC, Wang XH, Wang XM, et al. High efficient mammalianexpression and secretion of a functional humanizedsingle-chain Fv/human interleukin-2 molecules. World JGastroenterol 2006;12:3859.
42. Agadjanian H, Weaver JJ, Mahammed A, et al. Specific deliveryof corroles to cells via noncovalent conjugates withviral proteins. Pharmaceut Res 2006;23:367.
43. Edelweiss E, Balandin TG, Ivanova JL, et al. Barnase as anew therapeutic agent triggering apoptosis in human cancercells. PloS One 2008;3:e2434.
44. Shahied LS, Tang Y, Alpaugh RK, et al. Bispecific minibodiestargeting HER2/neu and CD16 exhibit improved tumor lysiswhen placed in a divalent tumor antigen binding format.J Biol Chem 2004;279:53907.
45. von Minckwitz G, Harder S, Hovelmann S, et al. Phase Iclinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients withadvanced solid malignomas. Breast Cancer Res 2005;7:R617.
46. Marshall KW, Marks JD. Engineering and characterization ofa novel fusion protein incorporating B7.2 and an anti-ErbB-2single-chain antibody fragment for the activation of Jurkat Tcells. J Immunother 2001;24:27.
47. Biburger M, Weth R, Wels WS. A novel bispecific tetravalentantibody fusion protein to target costimulatory activity forT-cell activation to tumor cells overexpressing ErbB2/HER2.J Mol Biol 2005;346:1299.
48. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can berendered specific for CD19: Toward the selective augmentationof the graft-versus-B- lineage leukemia effect. Blood2003;101:1637.
49. Jensen MC, Cooper LJ, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targetingB-cell malignancy. Cytotherapy 2003;5:131.
50. Yu K, Hu Y, Tan Y, et al. Immunotherapy of lymphomaswith T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma 2008;49:1368.
51. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapyfor indolent non-Hodgkin lymphoma and mantle cell lymphomausing genetically modified autologous CD20-specificT cells. Blood 2008;112:2261.
52. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocytecytotoxicity and proliferation directed by a single chimericTCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70.
53. Losch FO, Muller R, Mutschler B, et al. Activation of T cellsvia tumor antigen specific chimeric receptors: The role ofthe intracellular signaling domain. Int J Cancer 2003;103:399.
54. Patel SD, Ge Y, Moskalenko M, et al. Anti-tumor CC49-zetaCD4 T cells possess both cytolytic and helper functions. JImmunother 2000;23:661.
55. Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineeredT cells to target EGFRvIII expressing glioblastoma.J Neurooncol 2009;94:373.
56. Ren-Heidenreich L, Mordini R, Hayman GT, et al.Comparison of the TCR zeta-chain with the FcR gammachainin chimeric TCR constructs for T cell activationand apoptosis. Cancer Immunol Immunother 2002;51:417.
57. Morel PA, Oriss TB. Crossregulation between Th1 and Th2cells. Crit Rev Immunol 1998;18:275.
58. Mueller DL, Seiffert S, Fang W, et al. Differential regulationof bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptorin cloned CD4 + helper T cells. A model for thelong-term survival of memory cells. J Immunol 1996;156:1764.